Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
← catalyst calendarNCT05158894 · readout ≤ 3,451 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,884estimated
Sites
2
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-10 | actual | When the study began enrolling |
| Primary completion | Jan 2036 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2036 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Primary outcome
what the primary-completion date above is the date OFMajor Congenital Malformations (MCMs)
measured Up through the first 12 months of life
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed